alexa Cutaneous Leishmaniasis and the Strategies for Its Prevention and Control | OMICS International
ISSN: 2329-9088
Tropical Medicine & Surgery
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Cutaneous Leishmaniasis and the Strategies for Its Prevention and Control

Alidadi S and Oryan A*

Department of Pathology, School of Veterinary Medicine, Shiraz University, Iran

*Corresponding Author:
Oryan A
Department of Pathology
School of Veterinary Medicine
Shiraz University, Shiraz, Iran
Tel: 0711-2286950
E-mail: [email protected]

Received Date: February 25, 2014; Accepted Date: February 27, 2014; Published Date: February 28, 2014

Citation: Alidadi S, Oryan A (2014) Cutaneous Leishmaniasis and the Strategies for Its Prevention and Control. Trop Med Surg 2:e114. doi: 10.4172/2329-9088.1000e114

Copyright: © 2014 Alidadi S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Tropical Medicine & Surgery

Despite zoonotic leishmaniasis is considered as a public health problem worldwide, it is one of the most neglected diseases [1,2]. This disease is identified by an annual incidence of about 2 million cases and a prevalence of 12 million cases globally [3]. Leishmaniasis is the third most important vector-borne disease after malaria and filariasis [4]. The disease is caused by the intracellular protozoa of the genus Leishmania, is common in tropical and subtropical regions of the world and transmitted by phlebotomine sand flies [5]. The numbers of the leishmaniasis cases are increasing throughout because of some factors such as the lack of vaccines, the increased parasites resistance to chemotherapy and inability to controlling vectors. Depending on the tropism, leishmaniasis can be divided into at least four forms namely cutaneous leishmaniasis (CL), muco-cutaneous leishmanfilariasisiosis (MCL) or mucosal leishmaniasis (ML), visceral leishmaniosis (VL) also known as kala-azar, and post kala-azar dermal leishmaniasis (PKAL) [6,7]. Approximately three-quarters of incidence cases of leishmaniasis are related to CL [6]. Leishmaniasis can vary from a self-limiting cutaneous disease to a fatal visceral disease depending on the effecting species [8]. CL is characterized by the presence of one or more ulcers which may heal spontaneously or persist for period of some months [4]. Rarely, CL may be transformed into ML at the advanced stages, if untreated [9]. In the Old World, CL is caused by primarily Leishmania major, and then L. tropica, L. infantum, and L. aethiopica [1,10,11], while in the New World, it is caused by L. Mexicana, L. braziliensis, and L. guyanensis species [6,12]. The parasite Leishmania exists in the extracellular promastigote form, inside the midgut of the vector and culture media, and in the intracellular amastigote form, in the mammalian host [2,13]. Diagnosis of the disease is made based on demonstration of the parasite by methods such as fine-needle biopsy of lymph nodes, bone marrow aspiration, splenic puncture, skin scraping cytology and culture [3,10]. Cytology including touch smear and needle aspiration is cheap and performed with high sensitivity for the typical cases, but it may be unable to detect the atypical cases of leishmaniasis [14,15]. The serology tests are limited because of the probable cross reaction of antibodies with some diseases like toxoplasmosis and trypanosomiasis [15]. Other methodologies such as immunohistochemistry (ICH) and polymerase chain reaction (PCR) are preferably applied for supplementary diagnosis of the disease in particularly CL form [1,15-17]. Treatment of CL may be topical or systemic, on the basis of several factors such as Leishmania species, geographic regions and clinical manifestations [18]. For focal therapy, thermotherapy, cryotherapy, paromomycin ointment, local infiltration with antimonials may be promising options with less systemic toxicity. Systemic treatment is provided by using azole drugs, miltefosine, pentavalent antimonials, pentamidine and amphotericin B and its liposomal formulation [18,19].

Early diagnosis and appropriate treatment are important for the management and control of CL and due to the risk of developing the ML or MCL [4]. Since, the control and prevention of leishmaniasis based on chemotherapeutic treatments is expensive, toxic, and associated with high recurrence and resistance rate therefore, it is performed based on vector and reservoir control and vaccines [8]. However sand flies possess the biomechanical defensive mechanisms, they are suspected to insecticides [4,20]. Indeed, the application of insecticide-impregnated clothing and curtains and also implementing training programs for early diagnosis are promising and cost-effective preventive strategies for reducing leishmaniasis transmission [4]. Disease control and prevention are difficult and challenging because of the complexity of the control of the vectors and the reservoir hosts especially rodents and asymptomatic dogs [13,20-22]. Meanwhile, the protection of canine populations as an important reservoir of Leishmania species is crucial. Therefore, considerable attempts should be made towards monitoring of the prevalence and incidence of canine leishmaniasis and developing cost-effecting control strategies against this disease [20].

Development of a safe, efficient and cost-effective vaccine is the critical global public-health propriety [8]. An ideal vaccine developed against the disease should be efficient, safe, reproducible, and cost-effective and used for effective therapeutic and anaphylactic indications. Moreover, it must contain antigens sharing among several species, protect against infection and disease, and induce relevant T helper 1 and 2 cell responses [7,8]. Vaccine antigens should be maintained between species and thus cross-protective against different Leishmania parasite species [7]. Vaccines based on live Leishmania promastigotes harvested from cultures or leishmanization have adverse side effects including persistent lesions, psoriasis, as well as concerns of standardization and quality control, and immunosuppression [8]. The live-attenuated antileishmanial vaccines are still at their early stages of development [8] and the advances in the development of these live attenuated parasites may make a promising vaccine approach [7]. These vaccines offer a new approach to immunization against leishmaniasis, while there are concerns that the parasite may revert to a virulent form, and the destruction of the parasite due to deletion of essential virulence genes [7,8]. So, these may make the use of killed parasites more attractive for vaccine options [8]. Formulation of the first generation vaccines against leishmaniasis include whole killed or fractions of the Leishmania parasites is difficult to standardize [6,8]. These vaccines are inadequate to produce long lasting and relevant immune responses required for protection [6]. Second-generation vaccines composed of vaccines using recombinant viruses and bacteria as delivery vehicles expressing Leishmania parasite antigens [6,8]. These vaccines are safe because of they do not contain any pathogenic organism [8]. Thirdgeneration vaccines or DNA vaccines have some advantages such as stability, standardization, large-scale of manufacturing, and the possibility of combining different genes in one construct [6,8]. Some vaccines composed of sand fly saliva and salivary proteins alone or in combination with Leishmania antigens are under development. These vaccines have been designed on the basis of adverse impacts of the salivary proteins-induced immunity [12]. It seems that combined vaccines include multiple antigens and well-developed adjuvants have the most chances to succeed [6,8]. The selection of adjuvant and induction of Th1 response to protect against leishmaniasis are critical [8]. Therefore, the future researches should include appropriate adjuvants in order to design and fabricate an effective vaccine against leishmaniasis. Nevertheless, vaccination remains the most promising strategy for control of all forms of the disease.

Finally, collaboration among medical physicians, veterinarians, researchers, and public health authorities is critical to find a suitable platform and strategy for the control and prevention of leishmaniasis.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 12444
  • [From(publication date):
    March-2014 - Jul 23, 2018]
  • Breakdown by view type
  • HTML page views : 8567
  • PDF downloads : 3877

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7